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1. Introduction 
1.1 BK Virus 
BK virus is a polyomavirus belonging to the papovaviridae branch. In addition to BK, the 
human polyomavirus family includes John Cunningham virus (JCV), Washington 
University virus (WUV), Karolinska Institute virus (KIV) and Merkel cell viruses (Boothpur 
et al. 2010). BK virus is a virus without a shell and it has a double-stranded circular non-
enveloped DNA. It was first discovered and isolated in 1971 just like JC virus, responsible 
for Progressive Multifocal Leukoencephalopathy (PML). Contamination usually occurs 
during early childhood through the airway without clinical symptoms. BK virus 
seroprevalence in general population is around 60%. The main latency areas are the kidney 
and the urothelium. Asymptomatic BK virus infection is often acquired in childhood and the 
virus persists in a dormant state in urothelium and kidneys of healthy and 
immunocompetent individuals, where it can be reactivated under immunosuppression 
(Nickeleit et al. 2000a; Brocker et al. 2011). 
1.2 Prevalence and incidence 
Urinary viral prevalence for BK virus is between 0.3% and 6% in general population, and 
increases in functions of immunosuppression degree; between 10% and 45% in patients after 
renal transplant, 30% in patients after bone marrow graft and 25% in patients with Human 
immunodeficiency virus. In patients with renal graft, the annual incidence of the 
nephropathy is between 3% and 5% (Randhawa et al. 2000; Pavlakis et al. 2006). 
1.3 Risk factors 
BK virus-associated nephropathy seems to be promoted by the concurrent presence of 
several risk factors. The immunosuppressive regimen strength, with high level blood 
concentrations, is the first factor involved. Most patients affected by BK virus-associated 
nephropathy previously had an intensification of immunosuppressive regimen due to a 
rejection event or a treatment including tacrolimus and/or mycophenolate mofetil 
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combined with monoclonal or polyclonal antibodies (De Luca et al. 2000; Nickeleit et al. 
2000b; Randhawa et al. 2000; Hirsch et al. 2001). Conversely, no cases have been reported in 
patients treated with cyclosporine and corticosteroids (Binet et al. 1999; Mengel et al. 2003). 
The other risk factors identified comprise donor characteristics, such as female gender, 
deceased donation, ischemia-reperfusion injury, high BK virus specific antibody titres, HLA 
mismatch and African-American ethnicity. The recipient characteristics in cause are older 
age, male gender, white race, diabetes, obesity, retransplantation, lack of HLA C-7, low or 
absent BK virus specific T-cell activity. Lastly, in addition to high immunosuppressive drug 
levels and tacrolimus based combinations, other post-transplant factors can be mentioned as 
acute rejection and antirejection treatment, cumulative steroid exposure and lymphocyte 
depleting antibodies (Gupta & Gupta, 2011). 
Although immunosuppression increases the probability of latent BK virus reactivation, 
clinical manifestation of disease is rare. When symptoms occur, on the clinical point of view, 
a progressive decline of the renal functions can be observed up to 45 % of patients, usually 9 
to 12 months after the renal transplant (Nickeleit et al. 2000a; Randhawa et al. 2000). The 
most serious form of the infection turns out to be the interstitial nephritis; although the BK 
virus was discovered in the 70’s, this serious complication has first been seen in 1995. This 
fact can probably be explained by the commercialization of two drugs in 1995 and 1996, 
tacrolimus and mycophenolate mofetil. 
Interestingly, BK virus-associated nephropathy happens hardly only in patients with renal 
graft. Some explanations could be found, such as the role of vesico-urethral reflux, quite 
usual in renal transplantation, with the systemic pathway of collecting tubes in peritubular 
capillary and the tubular localization of the infection. Some authors evoked easiness in the 
viral antigens presentation in a context of allograft, cold ischemia, tubular necrosis and graft 
rejection. For that matter BK virus-associated nephropathy is generally related to rejection, 
both events being linked in time; most cases of nephropathy are falsely tagged and treated 
just like a rejection. This confusion suggests that rejection is a risk factor on its own. Viral 
antigens could probably lead to rejection and conversely a rejection event could reactivate 
viral replication. In mice, Atencio et al proved an inductive effect of tubular damage upon 
BK virus linked interstitial nephritis (Atencio et al. 1993). 
1.4 Clinical aspects 
BK virus infection may lead to encephalitis, retinitis, pneumonitis, damage of the kidneys, 
bleeding of the bladder, and blockage of urine passageways. Minor infections are most of 
the time asymptomatic and can lead to urethral stenosis. This infection occurs 1 to 45 
months (average 12.5 months) after the graft. It is linked to the conjunction of multiple 
factors, including an intense immunosuppressive regimen, viral reactivation, existence of an 
immune-allogenic conditions, and a suffering tubular due to ischemia or rejection (Nickeleit 
et al. 2003).  
1.5 Genotypes 
BK virus comes in the form of 4 different genotypes, type I being the most common seen. 
The coding regions for non structural proteins T and t antigens (pathogenic viral power), 
viral capsid proteins (cellular tropism) and a regulatory non coding zone have a vital 
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importance. Some authors have brought to light emerging mutations which could explain 
the renal physiopathologic effects of these viruses (Chen et al. 2001). Virus selection in 
patients with renal graft results in rearrangements in the T antigen region, mutations in the 
non coding regulatory zone, and above all variations in VP1 protein (Smith et al. 1998; 
Baksh et al. 2001; Randhawa et al. 2002). Heterogeneity and genetic instability in a same 
patient seem to favor renal damage and the risk of escaping immunologic surveillance 
(Chen et al. 2001; Randhawa et al. 2002). 
1.6 Histology 
BK virus is usually associated with changes in the kidney and sometimes haemorrhagic 
cystitis and urethral stenosis. The virus affects tubular epithelial cells that show 
characteristic intranuclear inclusion bodies. Diagnosis relies upon urinary cytology, 
detection of viral DNA in fluids and renal biopsy. The nephropathy diagnosis can only be 
made histologically in a graft biopsy. Intranuclear viral inclusions are exclusively seen in 
epithelial cells and tubular cells reveal focal necrosis. Four different variants of intranuclear 
inclusion bodies can be seen throughout the entire nephron. Type 1 is the most frequently 
observed; it is an amorphous basophilic ground-glass variant. Type 2 is an eosinophilic 
granular type, halo surrounded. Type 3 is a finely granular form lacking a halo. And finally 
type 4 is a vesicular variant presenting markedly enlarged nuclei and irregular chromatin. 
Infected cells which are rounded-up and extruded from the epithelial cell layer into tubular 
lumens are frequently observed. Viral replication often causes tubular epithelial cell necrosis 
with denudation of basement membranes. Although cytopathic signs can be seen along the 
entire nephron, they are mostly abundant in distal tubular parts and collecting ducts 
(Nickeleit et al. 2000a). 
1.7 Interstitial inflammation 
Interstitial inflammation in BK virus-associated nephropathy still remains controversial and 
needs to be fully explained. The major outcome is to distinguish between virally induced 
interstitial nephritis and cellular rejection. As lowering immunosuppression is the first 
option which can be chosen in the treatment, this choice requires two conditions, first the 
absence of rejection and second the BK virus should not trigger rejection. BK virus is 
frequently accompanied by an heterogeneous inflammatory reaction (Drachenberg et al. 
1999). This inflammation can be minimal or absent in up to 17% of biopsies (Nickeleit et al. 
2000a). When inflammation is encountered, the inflammatory cell infiltrate is composed of 
lymphocytes, macrophages and occasional plasma cells. Polymorphonuclear leukocytes can 
be seen in response to markedly damaged tubules with urinary leakage (Drachenberg et al. 
1999). About 50% of biopsies performed during persistent BK virus-associated nephropathy 
show evidence of cellular rejection as conventionally defined with abundant tubulitis and 
transplant endarteritis in about 25%. Typically, mononuclear cell infiltrates and tubulitis are 
pronounced in areas without viral inclusions making virally induced interstitial nephritis 
highly unlikely (Nickeleit et al. 2000a).  
The upregulation of MCH-class II (HLA-DR) and ICAM-1 on tubular epithelial cells is a 
typical finding in graft biopsies with cellular rejection and can serve as an adjunct diagnostic 
tool (Seron et al. 1989; Nickeleit et al. 1998). HLA-DR expression can stimulate an allogenic 
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lymphocytic reaction and also enhance T cell mediated lysis (Rosenberg et al. 1992). 
Consequently, BK virus could probably trigger rejection episodes by inducing HLA-DR 
upregulation as previously proposed for CMV (von Willebrand et al. 1986). However, no 
association could be found between BK virus infection and tubular HLA-DR expression 
based on immunofluorescence double labeling staining techniques. It is only in biopsies 
showing characteristic morphological evidence of rejection with marked tubulitis that 
typical upregulation of HLA-DR and ICAM-1 could be observed (Nickeleit et al. 2000a). 
Therefore, BK virus does not stimulate HLA-DR expression. Consequently no significant 
difference can be found between the prevalence of rejection in tissue samples taken during 
persistent BK virus-associated nephropathy and time matched controls without BK virus 
nephropathy. Thus, BK virus does not seem to provoke a constant and pronounced 
interstitial inflammatory reaction and should probably not be considered as associated with 
an increased prevalence of rejection episodes (Nickeleit et al. 2000a). 
1.8 PCR 
BK-virus DNA in the plasma and the urine, which can be detected by PCR (Polymerase 
Chain Reaction), is closely associated with nephropathy. Quantitative PCR can be used to 
follow the disease evolution and the treatment efficiency (Randhawa et al. 2004).  
As for BK virus infection, this technique has proven a 100% sensivity, a 88% specificity and 
above all a negative predictive test of 100%. Hirsch et al. have even shown a correlation 
between viral load and nephropathy and proposed a cut-off above which the risk of 
nephropathy is significant: all patients with more than 7700 copies/mL in plasma had 
typical BK virus-associated nephropathy lesions on the biopsy (Hirsch et al. 2002). 
The nephropathy evolution is very poor with a cytopathogenic effect persistent in up to 70% 
of patients, a graft loss in 45% of cases; and major sequel fibrosis in 75% of cases, even if 
viremia can be controlled (Nickeleit et al. 2000a; Randhawa et al. 2000; Mylonakis et al. 2001; 
Mengel et al. 2003). 
2. Classical treatments for BKV nephropathy 
Therapeutic alternatives are quite few in number. Despite the absence of randomized 
clinical trials, the current approach generally includes reduction of immunosuppression 
(Brennan et al. 2005; Hardinger et al. 2010). The rational is to allow host immune function to 
combat the virus, with the risk to increase acute and subclinical rejection. Lowering 
immunosuppression with smaller dosage and/or less drugs is partially efficient and seems 
to be the first thing to do. Except from lowering immunosuppression, to date no treatment 
seem to be efficient enough to be recommended to all patients, and new research have to be 
performed because of the poor evidence in small series of patients (Johnston et al. 2010). 
2.1 Lowering immunosuppression 
Reduction of immunosuppression is to date the only consensus regarding the treatment of 
BK virus-associated nephropathy. Lowering tacrolimus dosage of 41% and mycophenolate 
mofetil dosage of 44% allowed to eradicate 24 patients’ viremia in 6 months (Saad et al. 
2008). 
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In a previous study, mycophenolate mofetil was stopped the day leflunomide treatment was 
initiated; tacrolimus and everolimus were respectively reduced of 50% and 12.5%. Therapeutic 
drug monitoring target for tacrolimus was lowered to 4 - 6 ng/mL on immunoenzymatic 
techniques on whole blood. Corticosteroids were kept with average dosage of 5 to 10 mg per 
day (Bazin et al. 2009). Other authors recommend even lower targets with 3 ng/mL for 
tacrolimus and 100 ng/mL for cyclosporine (Gupta & Gupta, 2011). 
Besides, lowering immunosuppressive regimens together with a specific treatment for BK 
virus-associated nephropathy recently turns out to be effective to prolong graft survival, 
and moreover a safe treatment with acute rejection rates not increased significantly after 
lowering immunosuppression (Dheir et al. 2011). 
Two different therapeutic strategies have been evaluated: the immunosuppression withdrawal 
(3-drug to 2-drug immunosuppression) within the first month versus reduction of 
immunosuppression. The regimen modifications and results are presented in table 1 and 
figure 1. The Withdrawal cohort had significantly better graft survival at 1 year compared with 
the Reduction cohort (1-year graft survival 87.8% versus 56.2%, P = 0.03) (Weiss et al. 2008). 
 
 
Withdrawal 
cohort 
(n = 17) 
Reduction 
cohort 
(n = 18) 
p 
CNI, sirolimus, prednisone at diagnosis 
CNI, MMF, prednisone at diagnosis 
Median serum creatinine at diagnosis (mg/dl) 
Agent withdrawal within 1 mo of diagnosis 
CNI withdrawal 
AP withdrawal 
Dose reduction within 1 mo of diagnosis 
CNI reduction, AP reduction < 50% 
CNI reduction, AP reduction ≥ 50% 
Tac to CsA switch, AP reduction < 50% 
Ancillary therapy 
Cidofovir 
Intravenous Ig 
Leflunomide 
Acute rejection after diagnosis 
12 
5 
2.5 
 
14 
3 
 
- 
- 
- 
 
2 
8 
4 
1 
11 
7 
2.2 
 
- 
- 
 
8 
7 
3 
 
5 
8 
5 
1 
0.56 
0.56 
0.30 
 
- 
- 
 
- 
- 
- 
 
0.40 
0.88 
1.0 
1.0 
Table 1. Immunosuppression modifications comparing immunosuppression withdrawal 
versus immunosuppression reduction after diagnosis of BK virus-associated nephropathy. 
CNI, calcineurin inhibitor; MMF, mycophenolate; AP, antiproliferative; Tac, tacrolimus; 
CsA, cyclosporine A (Weiss et al. 2008). 
2.2 Cidofovir 
Cidofovir (Vistide®) is an injectable antiviral drug. It belongs to nucleoside analogues. It is 
used in infections due to human Cytomegalovirus (CMV) in adults suffering of AIDS 
(Acquired immune deficiency syndrome) without renal insufficiency, and it should only be 
used when other treatments are considered as inappropriate. Cidofovir counters CMV 
replication thanks to a selective inhibition of viral DNA polymerase in herpesviridae viruses 
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Fig. 1. Immunosuppression withdrawal preserves graft function compared with reduction 
(Weiss et al. 2008). 
 (Gilead 2010). Cidofovir has also demonstrated in vitro activity against murine and simian 
polyomavirus strains and appears to have activity against JC virus in vivo (De Luca et al. 
2000). Pharmacokinetic studies have demonstrated that cidofovir is highly concentrated in 
urine and renal tissue which are the primary sites of BK virus infection (Kadambi et al. 
2003). This fact highlights the possibility that low doses might be sufficient for treating an 
infectious process, such as BK virus-associated nephropathy, that appears to be largely 
localized to the kidney and genitourinary tract. 
The treatment consists in a low-dose treatment, 0.25 mg/kg/day intravenous during 2 
weeks, associated to a prior hydration of 1 litre of saline solution. Cidofovir seems to be 
efficient in BK virus as well, but it tends to concentrate itself inside the kidney and can be 
responsible of a nephrotoxicity mostly for tubular cells leading to renal insufficiency. 
Few cases have been described in literature and no conclusion can be given on the real 
efficacy of cidofovir. Indeed, despite viremia control, viruria remains detectable and the 
treatment is not able to avoid the evolution towards fibrosis and renal insufficiency 
(Kadambi et al. 2003; Kuypers et al. 2005). 
In some cases, cidofovir may also become deleterious (Pallet et al. 2010; Talmon et al. 2010). 
3. Leflunomide 
3.1 Drug generalities 
Leflunomide (Arava®) is a disease-modifying antirheumatic drug (DMARD) used in adult 
patients with methotrexate intolerance, failure or loss of efficiency; it is also used in a second 
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line to treat severe and active forms of psoriatic arthritis (Maddison et al. 2005; Sanofi-
Aventis 2009). 
3.2 Pharmacodynamy 
Its immunosuppressive action lies in the dihydroorotate dehydrogenase (DHOH) inhibition, 
an enzyme necessary for de novo synthesis of pyrimidic bases in lymphocytes. It also has an 
anti-proliferative action (Williamson et al. 1995; Fox et al. 1999). 
Besides, leflunomide has proven abilities to reduce the viral proliferation for Human 
Cytomegalovirus (CMV), Herpes Simplex Viruses (HSV) in vitro (Knight et al. 2001) and 
respiratory syncytial virus (RSV) in vitro and in vivo (Dunn et al. 2011).  
3.3 Pharmacokinetics 
After per os administration, leflunomide is promptly and almost fully metabolized into its 
active form, terflunomide or A77 1726. This metabolism happens during first pass and 
consists in a carbon cycle opening in the intestinal wall and the liver. 95% of leflunomide is 
turned into A77 1726 this way, the remains into minor metabolites. Terflunomide is the drug 
responsible for the activity and side effects of leflunomide. 
Leflunomide bioavailability is about 82% in healthy volunteers (Sanofi-Aventis 2009). 
Elimination plasma half-life of A77 1726 is quite considerable, with some 15 days in average. 
Patients are so compelled to take a 100 mg charging dose for 3 days before a 10 to 20 mg 
maintenance dose per day. 
After a unique charging dose, A77 1726 Tmax is comprised between 6 and 12 hours, with a 
high inter-individual variability in patients with rheumatoid arthritis (Rozman 2002).  
The volume of distribution (Vd) is quite low, with about 12.7 L (6 to 30.8 L), which is logical 
with its high affinity and linkage to albumin (99.4% in healthy volunteers) (Rozman 2002). 
Elimination of A77 1726 is slow, it is characterized by an apparent clearance of 0.051 L/h 
(Rozman 2002). This elimination is mostly renal (43%) and biliary (48%), as a consequence 
renal insufficiency alone does not significantly impair A77 1726 plasma concentrations 
(Beaman et al. 2002). Furthermore haemodialysis does not modify concentrations or 
clearance of A77 1726, which allows the patients to be on a dialysis without any dose 
adjustment. In vitro studies showed that cytochroms P450, in particular cytochroms 1A2, 
2C19, 3A4 and 3A5 were involved in leflunomide metabolism (Kalgutkar et al. 2003). A 
pharmacogenetic study also showed the link between a polymorphism of cytochrom 1A2 
and a risk of toxicity for patients with rheumatoid arthritis (Bohanec Grabar et al. 2008). 
3.4 Predictive efficiency 
In rheumatoid arthritis, plasma concentrations above 13 µg/mL seem to be efficient. These 
concentrations are usually reached with 20 mg per day dosage (van Roon et al. 2005). Some 
authors tried to establish a relation between plasma concentrations and efficiency in patients 
with BK virus nephropathy, showing a tendency but with no absolute proof. Finally to date, 
no link between plasma concentrations and side effects has been shown (Bazin et al. 2009). 
Yet in vitro studies seem to show a predictive correlation between concentrations and the 
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viral inhibitory effect: 10 µg/mL reduced the extracellular BKV load by 90% (IC90) but with 
significant host cytostatic effects (see figure 2) (Bernhoff et al. 2010). 
 
Fig. 2. Effect of Terflunomide on BK Virus load in vitro (Bernhoff et al. 2010) 
3.5 Mechanism of action 
Researches about the mechanism of leflunomide have recently been brightened. 
Leflunomide has two mechanisms of action: inhibition of dihydroorotate dehydrogenase, a 
key enzyme in the pyrimidine synthesis pathway, and tyrosine kinase inhibition. 
Dihydroorotate dehydrogenase inhibition is the primary mechanism involved in 
rheumatoid arthritis treatment. Interactions between the BK virus and the cellular protein 
kinase AKt / mammalian target of rapamycin (mTOR) pathway have been discovered 
(Liacini et al. 2010). These interactions are described in figure 3. 
Akt (protein kinase B) is a serine/threonine kinase activated by growth factors, cytokines 
and mitogens (Fayard et al. 2010). The mTOR pathway which controls protein synthesis is 
located downstream of Akt. Akt indirectly activates mTOR. Two mTOR complexes have yet 
been described, mTOR complex 1 (mTORC1) which controls translation initiation, and 
mTOR complex 2 (mTORC2) which controls cytoskeletal changes and is also a 3’-
phosphoinositide-dependent kinase-2 (PDK2), phosphorylating Akt, which may alter its 
substrate specificity (Bhaskar et al. 2007). Liacini et al showed that BK virus infecting renal 
tubular epithelial cells was able to activate the Akt/mTOR pathway; that leflunomide active 
metabolite, A77 1726 could inhibit PDK1 and Akt phosphorylation in a dose-dependent 
manner and in this way to reduce BK large T antigen expression and DNA replication. The 
combination of serine/threonine kinase inhibition of mTOR and tyrosine kinase inhibition 
significantly reduce the ability of the virus to survive and to produce new virions. More 
interesting though seems to be the combination of leflunomide and sirolimus targeting the 
Akt/mTOR pathway on different sites. Because both leflunomide and sirolimus possess 
immunosuppressive activity, this combination may allow treatment of BK virus-associated 
nephropathy without reduction of immunosuppression (Liacini et al. 2010). 
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Fig. 3. Interactions between BK virus and inhibitors, sirolimus and leflunomide (Liacini et al. 
2010) 
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Results in terms of biological evolution in patients speak for itself. In a mean monitoring 
time of 16 months (12-24 months), viral load with leflunomide can be reduced about up to 
50%, and even be brought to undetectable, in blood like in urine. But more important is the 
lowering of renal failure and graft rejection thanks to this treatment. Creatinine clearance 
(Cockroft-Gault) can be stabilized and even improved (Bazin et al. 2009). 
3.6 Therapeutic drug monitoring 
Initial dosage for leflunomide is 20 mg once a day, and can be raised to 30 or 40 mg for 
patients with viral loads remaining important. Plasma concentrations in therapeutic drug 
monitoring fluctuate between 15 and 135 µg/mL. These concentrations set out low intra-
individual but high inter-individual variability, and moreover without apparent correlation 
with prescribed dosage. It is interesting to notice that these concentrations were outside 
usual targets used in most studies - 50 to 100 µg/mL - which are supposed to offer the best 
efficiency and to limit the hepatotoxicity risk which can be lethal. Besides, the patient with 
the highest concentration - 135 µg/mL - had its viremia turned undetectable after only a two 
months treatment and showed no side effect of any kind. This result suggests that higher 
concentrations lead to higher efficacy and vice versa (Bazin et al. 2009). 
3.7 Tolerance 
Concerning tolerance, very few patients suffer from serious side effects. Loss of taste or 
lethargy can be observed but without any correlation with plasma concentrations. These 
side effects can prompt the treatment to be stopped, but in most cases viremia tends to 
increase strongly (Bazin et al. 2009). 
4. Discussion 
The main risk factor for BK virus-associated nephropathy is undeniably the 
immunosuppressive regimen intensity, in particular an intensification due to an acute 
rejection event (Binet et al. 1999; Nickeleit et al. 2000a; Barri et al. 2001; Nickeleit et al. 2003). 
Drugs in cause for these events seem to be the combination of tacrolimus, mycophenolate 
mofetil and monoclonal or polyclonal antibodies (Binet et al. 1999; Nickeleit et al. 1999; 
Nickeleit et al. 2000a; Nickeleit et al. 2003; Benavides et al. 2007). The organ and the graft 
type also play a role. For instance, Benavides et al. showed that the incidence of BK virus-
associated nephropathy is higher in patients with kidney and pancreas rather than kidney 
alone; and that an alive donor would had a protective effect, probably explained by a lighter 
immunosuppressive regimen (Benavides et al. 2007). 
Other risk factors have been evoked, like age and sex: nephropathy incidence seem to be 
greater for aged men (Ramos et al. 2002). 
Furthermore many patients improve their symptoms at a distance of the surgery with the 
lowering of immunosuppression. We already have at our disposal a few experimental 
studies testing leflunomide on chronic or acute graft rejection (Williams et al. 1994; Xiao et 
al. 1995; Shen et al. 1998). More recently the inhibitory effects of leflunomide upon HSV, 
CMV and BK virus have been proved in vitro like in vivo (Waldman et al. 1999; Waldman et 
al. 1999; Knight et al. 2001; Farasati et al. 2005). Indeed a study suggests leflunomide is at 
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least as efficient as ganciclovir in CMV infections and does not seem to be affected by 
resistant viruses (John et al. 2004). Leflunomide has even be successfully used in a patient 
with bone marrow graft and infected by a resistant virus to ganciclovir, foscarnet and 
cidofovir (Avery et al. 2004).  
The studies where leflunomide is used as an immunosuppressive drug in renal and hepatic 
graft are more and more, because leflunomide allows to reduce anti-calcineurin drugs which 
have the major inconvenient of nephrotoxicity, and potentially protects aside from CMV, 
HSV and BK virus infections (Hardinger et al. 2002; Williams et al. 2002). Moreover 
leflunomide seems to be an interesting alternative in BK virus-associated nephropathy in 
renal transplant by eradicating detectable viremia in some patients. Leflunomide also allows 
avoiding rejection in most cases in spite of classical immunosuppressive drugs dosage 
reduction. Besides one of leflunomide’s main asset is its absence of renal toxicity, contrary to 
cidofovir (Williams et al. 2005; Josephson et al. 2006; Teschner et al. 2006; Faguer et al. 2007). 
Thanks to the encountered success in renal transplant, leflunomide is now used to treat 
hemorrhagic cystitis linked to BK virus in bone marrow transplant (Dropulic et al. 2008). 
However, due to the absence of randomized clinical trials with a sufficient number of patients, 
some authors consider its use in a first-line drug not recommended (Chon et al. 2011). 
Leflunomide pharmacokinetics is characterized by a great inter-individual variability with 
terflunomide concentrations from 15 to 130 µg/mL obtained with the same dosage (Bazin et 
al. 2009). In BK virus infection, terflunomide concentrations between 15-30 µg/mL and 35-
100 µg/mL are sufficient to suppress respectively 50% and 90% of the replication for CMV 
and BK virus in vitro. That is why a therapeutic margin between 50 and 100 µg/mL has been 
proposed in this indication (Josephson et al. 2006). However, current strategic therapy so as 
to limit BK virus incidence tends to manage an early reduction of immunosuppressive 
regimen to avoid the apparition of a nephropathy. A prospective study with a significant 
number of patients would be probably necessary to definitely conclude about this relation 
between plasma concentrations and efficacy or in terms of rapidity of viral load eradication. 
5. Conclusion 
Leflunomide appears to be an alternative treatment in nephropathy due to BK virus in 
addition to lower immunosuppression regimen. In case of leflunomide use, a major 
standard seems to be high plasma terflunomide concentrations so as to obtain rapid virus 
eradication. Concentrations comprised between 15 and 60 µg/mL appear to be pertinent; 
these concentrations are usually reached with 20-40 mg per day. In patients with insufficient 
concentrations, further studies should be carried out to determine whether exists a benefit to 
use higher dosage up to 60 or 80 mg a day. Even if tolerance is quite satisfying, it will 
probably be the most important parameter in such high-dose treatments. 
Despite the small number of studies and the weak number of patients in each of them, a 
correlation seems to exist between plasma terflunomide concentrations and the treatment 
efficacy. This relation has not yet been proved with tolerance. 
Due to its great inter-individual variability and alongside classical virological and clinical 
follow-up therapeutic drug monitoring appears to be an important step to take into care 
patients with BK virus related nephropathy.  
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